Chinese may be the first to use CRISPR/Cas9 technology in humans

David Cyranoski, Nature News, 21 July 2016,

A Chinese group led by Lu You, an oncologist from Sichuan University’s West China Hospital, has received approval from the hospital review board to use CRISPR/Cas9 therapies in individuals with metastatic non-small cell lung cancer who have not responded to traditional treatments.  The treatment will involve the extraction of T cells from the patient’s blood followed by the use of CRISPR/Cas9 technology to knockout PD-1, which inhibits the ability of T cells to launch an immune response.  This study is similar to one previously approved by the NIH that will also knock out PD-1, however the US study will also knock out two additional genes.


Author: Advanced Analytical

Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare.

Leave a Reply